Roweka, I'm not expecting a very good NPAT due to the...

Roweka, I'm not expecting a very good NPAT due to the writedowns. It's this FY that I'm more enthusiastic about with EBITDA likely to exceed $8-8.5 mil thanks to C2B's immediate earning accretive contribution, its organic growth and "seamless" integration with MBE's platform which is also likely to increase MBE's overall margins.

MBE could also surprise on the upside each 1/4 which is what they did for 3 years leading to a SP of 44c, albeit with a DCB premium.

My point is I'm not seeing much downside risk as long as the audited numbers don't have any unpleasant surprises.

Now we have Q on board given its incredible low value, anything could happen.